Brief: Mindset Pharma announced Exclusive Licensing Agreement For Cybin To Acquire Intellectual Property Rights For Subset Of Co's Preclinical Compounds
27/09/2022 12:54
Sept 27 (Reuters) - Cybin Inc CYBN.NLB :
* MINDSET PHARMA - ANNOUNCED EXCLUSIVE LICENSING AGREEMENT
FOR
CYBIN TO ACQUIRE INTELLECTUAL PROPERTY RIGHTS FOR SUBSET OF CO'S
PRECLINICAL COMPOUNDS
* MINDSET PHARMA - CYBIN WILL LICENSE INTELLECTUAL PROPERTY
RELATED TO PRECLINICAL COMPOUNDS WITHIN MINDSET'S "FAMILY 1"
PORTFOLIO, EXCLUDING MSP-1014
Source text for Eikon: ID:nGNX3KWb73
Further company coverage: CYBN.NLB
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Mindset pharma
See all newsStifel GMP sees significant uncertainty for Reunion Neuroscience over lawsuit
Brief: Reunion Neuroscience Files Lawsuit Against Mindset Pharma
Brief: Mindset Pharma announced Exclusive Licensing Agreement For Cybin To Acquire Intellectual Property Rights For Subset Of Co's Preclinical Compounds
Brief: Mindset Pharma Receives Scientific Advice From UK Regulator Facilitating Advancement Of Phase 1 First-In-Human Clinical Trial Plan
Brief: Mindset Pharma Enters Manufacturing Agreement With Leading CDMO To Produce Pharmaceutical Grade Batches Of Next-Generation Psilocybin Drug Candidate, Msp-1014